Here are Monday’s biggest calls on Wall Street:
UBS reiterates Nvidia as buy
UBS lowered its price target to $240 per share from $300 ahead of earnings on Tuesday. “We expect NVDA to beat FQ3 (Oct) revenue by ~$3-4B (e.g. as much as ~$111-112B) and we see FQ4 (Jan) revenue guidance in the ~$130B range (Street ~$125B) and revenue ultimately coming in even higher than this as Rubin remains on track to ramp substantially in FQ4.”
JPMorgan reiterates Tesla as neutral
JPMorgan said it’s getting more constructive on the company’s robotaxi opportunity. “TSLA’s recent rapid ramp of its robotaxi fleet and ride-hailing operations, including this weekend’s launch of customer Cybercab sales, is starting to present early validation of the company’s unique advantage in physical AI, with deep vertical integration across software, manufacturing, and compute.”
Citi reiterates SpaceX as buy
Citi raised its price target on SpaceX to $280 per share from $240. “Not only does Flight 15 itself – the successful catch of the Starship using Mechazilla’s arms – represent one of the key milestones we’ve flagged along a multi-year path of upside toward $900+, but we walked away from the event with greater conviction in the outlook for the company’s Super Intelligence segment as well.”
Goldman Sachs reiterates CoreWeave as buy
Goldman lowered its price target but says it’s sticking with the stock. “We remain Buy rated and adjust our 12-month price target to $101 (from $106) based on 15x EV/EBIT to CoreWeave’s SNTM non-GAAP EBIT.”
Barclays reiterates Eli Lilly as overweight
Barclays raised its price target on Eli Lilly to $1,550 per share from $1,400. “Pricing will remain the debate, but the volume opportunity keeps getting bigger. Reiterate OW rating and $1,550 PT.”
Northcoast downgrades Costco to neutral from buy
Northcoast downgraded the stock on valuation. “Following the dividend announcement, Costco’s stock made a final push towards, and just above, our $1,100 price target.”
RBC upgrades Humana to outperform from sector perform
RBC said it sees earnings potential. “We are upgrading HUM to Outperform (from SP) to reflect the company’s impressive Stars turnaround, which, alongside disciplined medical cost management amid 23% individual MA membership growth this year, demonstrates significant earnings potential.”
Cantor Fitzgerald initiates Centrus Energy as overweight
The firm called the nuclear company “durable.” “We are initiating coverage of Centrus Energy with an Overweight rating and 12-month price target of $130.”
Comments